23:10 , Mar 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer; autoimmune disease

INDICATION: Solid tumors; Crohn’s disease; inflammatory bowel disease (IBD) In vitro, cell culture and mouse studies suggest inhibiting CDK9 and GSK3 could help treat cancer, Crohn’s disease and ulcerative colitis. Chemical synthesis and in vitro kinase...
23:08 , Mar 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture studies suggest inhibiting CDK9 could help treat castration-resistant prostate cancer (CRPC) that is resistant to BET bromodomain protein inhibitors. In a human BET inhibitor-resistant CRPC cell line, siRNA targeting CDK9 or...
16:06 , Jun 27, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Epithelial cancer; leukemia; lymphoma In vitro and cell culture studies suggest inhibiting hyperphosphorylation of BRD4 could help treat NUT midline carcinoma (NMC) and other cancers. In human NMC, leukemia and lymphoma cell lines, levels of...
21:08 , Dec 30, 2016 |  BC Week In Review  |  Company News

Sumitomo, Tolero deal

Sumitomo will acquire Tolero for $200 million up front, up to $430 million in development milestones and up to $150 million in sales milestones. The deal will provide Sumitomo with alvocidib flavopiridol, which has completed...
00:11 , Dec 22, 2016 |  BC Extra  |  Company News

Sumitomo acquiring Tolero

Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) will acquire oncology and hematology company Tolero Pharmaceuticals Inc. (Lehi, Utah) for $200 million up front plus milestones. The deal provides Sumitomo with alvocidib (formerly HMR 1275), a cyclin...
07:00 , Sep 29, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Caspase-3 (CASP3; CPP32); cyclin dependent kinase (CDK)

Infectious disease INDICATION: Viral infection Cell culture studies suggest the pan-caspase inhibitor emricasan, the generic antihelminthic niclosamide or CDK inhibitors could help treat Zika. In a Zika virus-infected human glioblastoma cell line, screening of 6,000 approved drugs,...
08:00 , Dec 14, 2015 |  BioCentury  |  Product Development

Following CoMMpass

Amidst a flood of promising data for hot targets, indications and technologies at this year's American Society of Hematology meeting, one collection of presentations stands out not only for the wide-reaching implications of their data,...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Company News

Eutropics, Tolero Pharmaceuticals deal

Eutropics granted Tolero exclusive rights to use Eutropics’ Praedicare-Dx biomarker platform in the development of Tolero’s alvocidib. The companies partnered in 2014 to use platform to predict responses to Tolero’s compounds to treat hematological malignancies....
07:00 , Sep 29, 2014 |  BC Week In Review  |  Company News

Eutropics, NIH pharmacogenetics news

Praedicare-Dx identifies alterations in apoptosis signaling pathways in cancer cells and stratifies leukemia and myeloma patients based on the likelihood of responding to treatment. The assay is being tested as a companion test for therapies...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

Alvocidib: Interim Phase II data

Interim data from an open-label, U.S. Phase II trial in 165 patients with previously untreated AML showed that 1 cycle of alvocidib plus cytarabine and mitoxantrone led to a complete response rate, the primary endpoint,...